

CLAIMS

1. An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH₂ (447).

2. An antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH₂ (447).

3. The antibody subtype according to claim 1 or 2 wherein the heavy chain of the native humanized PM-1 antibody corresponding to the subtype according to claim 1 or 2 has an amino acid sequence set forth in SEQ ID NO: 1.

4. The antibody subtype according to claim 3 wherein glutamine (Gln) at the heavy chain N-terminal is pyroglutamic acid (pGlu).

5. The antibody subtype according to any one of claims 1 to 4 wherein the light chain of the above humanized PM-1 antibody subtype has an amino acid sequence set forth in SEQ ID NO: 2.

6. A pharmaceutical composition comprising either the subtype (1) or the subtype (2) described in any one of claims 1-5, or both of the subtypes (1) and (2).